Email piyush.patel@visiongain.com for early bird discount

1. 2nd Annual
Cell-Based Assays
Optimising methods and integrating new platforms for drug discovery, development and toxicity testing
11th – 13th October 2011, Visiongain Conference Centre, London, UK BOOK NOW!
Key Speakers
Julie Holder, Preclinical Director, Stem Cell DPU, GlaxoSmithKline
Stefan Otto Mueller, Director, Early, Genetic and Molecular Toxicology, Merck Serono
Rachel Russell, Director, Primary Pharmacology Group, Pfizer
Darren Cawkill, Associate Director, Primary Pharmacology Group, Pfizer
Miroslav Cik, Research Fellow, Janssen Pharmaceutica (Johnson & Johnson)
Joanne Bowes, Principal Scientist, AstraZeneca
Magalie Rocheville, Investigator, GlaxoSmithKline
Stephen Minger, Global Head of R&D, Cellular Technologies, GE Healthcare
Frank W. Bonner, Chief Executive, Stem Cells for Safer Medicines
Mark Slack, Group Leader, Cellular Assays, Evotec
Jasmin Fisher, Researcher, Executable Biology, Microsoft Research Cambridge
Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine, Imperial College London
David C. Hay, Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh
Stefan Przyborski, Founder and Chief Scientific Officer, Reinnervate
Pre-conference Workshop, Tuesday 11th October, 2011
Industrial application of pluripotent stem cells and their derivatives- High-content screening as a valuable tool for drug discovery and toxicity testing
Led by: Mikael Englund, Senior Scientist, Site Manager, Cellartis, Daniella Steel, Senior Scientist, Project Leader, Cellartis,
Paul Andrews, Senior Scientist, Drug Discovery Unit, University of Dundee
Panellists: Petter Björquist, Senior Principal Scientist, Project Manager, Cellartis, Anders Aspegren, Senior Scientist, Production Manager, Cellartis
Associate Sponsor P H O T O N I S O U R B U S I N E S S
Organised By
Driving the Industry Forward | www.futurepharmaus.com
Media Partners
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/cell-based-assays

2. Conference Introduction
2nd Annual Cell-Based Assays
11th - 13th October 2011, London, UK
Dear Colleague, Associate Sponsor:
t takes well over £500 million and between 10 and 12 years to develop a new drug.
I InvivoSciences LLC is a frontier in developing next generation 3D cell
For every million compounds screened, approximately 250 make it to pre-clinical culture and assay systems, providing unprecedented solutions for
testing, 10 advance to clinical trials and just one is approved for patient use. Industry biomedical research, cosmetics, discovery, and toxicology screening. Two-
can ill-afford to continue such a wasteful process. dimensional cell cultures used during early phase research do not reflect
ancerous and animal cells, many having been in continuous culture for decades,
C the real, internal, 3D environment, and falsely indicate potential results
poorly reflect patient physiology. These, finally, are yielding to more representative from animal studies. Application of our products, a high-throughput
screening device (Palpator ) and plastic consumables for 3D cell culture systems, can
TM
models that better reflect the intended recipients of new molecular entities.
Advances in label-free technologies, human primary, 3D and embryonic-stem cell narrow this gap. The system precisely, rapidly, and cost-effectively quantifies the effects
derived lines are heralding a paradigm shift in drug discovery, development and of drug candidates, chemicals, and gene products on the physiological properties of
toxicity testing. reconstituted tissues (3D cell cultures), better reflecting in vivo tissue/organ functions.
ocussing on these, the future tools that better reflect PK/PD, genomic and
F For further information please visit: www.invivosciences.com
phenotypic differences within and between human populations, Visiongain brings Lonza is one of the world’s leading suppliers to the pharmaceutical,
you its second Cell-Based Assays conference. healthcare and life science industries. Lonza’s Bioscience Division
Attending this event will empower you to: provides innovative, reliable products and services for drug discoverycell
biology and molecular biology research and preclinical screening. We focus on primary cell
• Utilise new techniques in high throughput screening. supply, including diseased cells, stem cell derived cells, immortalized cells, biosensor cells,
• dentify intracellular transduction cascades for G-protein coupled receptors and
I transfection of difficult cells and cell expansion services. We also offer improved prediction
kinases. from cell models, including contextual cell-based assays for toxicity and mechanism-of-action
• Accelerate high-content screening using primary cells. assessment. We make reagent production easier for our customers with our Cells on Demand™
Services and putting the assays you already use into biologically relevant primary cells.
• ncorporate computational models to study the effects of drugs on intracellular
I
networks. For further information please visit: www.lonza.com
• se 3D cell assays for more relevant testing of the effects of drugs on organs,
U Scottish Biomedical offers a full range of biology services from
including the liver, heart and brain cells. protein expression and expression optimisation through to in
• arness human embryonic, adult and induced pluripotent stem cells for drug
H vitro screening, cell based assays and in vivo models. Our team
discovery, development and toxicity testing. will design and validate unique assays to suit your specific needs, using primary cells
or custom made cell lines of your choice. As experts in cell signaling, we specialise in
I look forward to meeting you at the conference cell-based and in vitro assays to determine compound effects on targets such as PDEs,
Best regards HDACs, ion channels, GPCRs, and kinases.
For further information please visit: www.scottish-biomedical.com
Hamamatsu Photonics is a world-leading manufacturer of
P H O T O N I S
optoelectronic components and systems and provides solutions for
O U R B U S I N E S S
Nicholas Stone a wide variety of applications including imaging devices for Life
Sciences. We will introduce our camera-based dispensing and imaging range, the FDSS
Head of Conferences series for fluorescence and luminescence. The FDSS7000 is a fully modular HTS system
and the FDSSµCELL is specifically designed for small throughput and assay development.
Based on our famous camera range the FDSS series provides high sensitivity and fast
readout times of a few minutes.
Who should attend? For further information please visit: www.hamamatsu.co.uk
Presidents, Chief Executive Officers, VPs, Global Heads, Chief Scientific Merck Millipore is the Life Science division of Merck KGaA of Germany
Officers, Directors, Principal Scientists, Franchise Heads and Investigators in:
and offers a broad range of innovative, performance products, services
and business relationships that enable our customers’ success in
• High-Throughput/High-Content Screening Operations research, development and production of biotech and pharmaceutical
• Bioanalytical Development drug therapies. Through dedicated collaboration on new scientific and
• Compound Profiling engineering insights, and as one of the top three R&D investors in the Life Science Tools
• Drug Discovery/Validation industry, Merck Millipore serves as a strategic partner to customers and helps advance the
• Cellular Imaging promise of life science. Headquartered in Billerica, Massachusetts, the division has around
• Lead Generation 10,000 employees, operations in 64 countries and pro forma 2009 revenues of $2.9 billion.
• In Vitro Sciences Merck Millipore operates as EMD Millipore in the U.S. and Canada.
• ADMET For further information please visit: www.merckmillipore.com
• Pre-clinical Development
• Medicinal Chemistry Media Partners:
• Toxicology PharmiWeb.com is the leading industry-sponsored portal for
• Stem Cell Technologies & Platforms the pharmaceutical sector. Supported by most of the leading
• Pharmacovigilance and Safety Testing pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features,
• Chemistry and Bioapplications events listings and international jobs to industry professionals across Europe and the US.
• GPCR/Kinases/Molecular Pharmacology
• External/Contract Research
For further information please email: corporate@pharmiweb.com
• Pharmacokinetics/Pharmacodynamics BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD.
• Cellular Research and Development It is based and located in Warsaw, Poland. Biotechnology World
• Business Development was founded in 2007 to provide the world’s biotech and pharma
• Investment and Venture Capital information and market to make it universally accessible and useful for scientific and business
processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE
platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY
EUROPE offers companies completed internet public relations, publication and marketing
solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and
Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities.
Sponsorship and exhibition opportunities
For further information please visit: www.biotechnology-europe.com
This event offers a unique opportunity to meet and do business with some of the key
Future Pharmaceuticals has forged powerful relationships with
Driving the Industry Forward | www.futurepharmaus.com
players in the pharmaceutical and biotech industries. If you have a service or product to key industry leaders to provide a platform for successful brand
promote, you can do so at this event by: recognition, and for senior decision-makers to have the means
• Hosting a networking drinks reception to procure and plan implementation strategies based on the topics covered. Positioned to
be an authoritative resource within top pharma companies as well as small, specialty, and
• Taking an exhibition space at the conference biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a
• Advertising in the delegate documentation pack highly targeted and responsive audience, bridging the gap between the industries’ top issues
• Providing branded bags, pens, gifts, etc. and the solutions top-tier vendors can provide.
If you would like more information on the range of sponsorship or exhibition possibilities For further information please visit: www.futurepharmaus.com
for visiongain's 2nd Annual Cell-Based Assays Conference, please contact us: InPharm is the online platform for exclusive pharmaceutical
news, comment, contracts, services, jobs and events and is
Damian Gorman, +44 (0)20 7549 9934 home to InPharmjobs.com, Pharmafile and Pharmafocus.
damian.gorman@visiongainglobal.com For further information please visit: www.In-Pharm.com

3. Pre-Conference Interactive Workshop
2nd Annual Cell-Based Assays
Tuesday 11th October 2011
Industrial application of pluripotent stem cells and their derivatives
High-content screening as a valuable tool for drug discovery and toxicity testing
Led by: Mikael Englund, Senior Scientist, Site Manager, Cellartis Panellists: Petter Björquist, Senior Principal Scientist, Project Manager, Cellartis
Daniella Steel, Senior Scientist, Project Leader, Cellartis Anders Aspegren, Senior Scientist, Production Manager, Cellartis
Paul Andrews, Senior Scientist, Drug Discovery Unit,
University of Dundee
Timings: About your workshop leaders:
09:30 Registration and coffee
An introduction to pluripotent stem cells, Industrialisation of stem cells
Introduction to high-content screening and assay design
Screen execution and follow-up Mikael Englund
12:40 Lunch
13:40 Case studies, lessons learnt, Stems cells in predictive toxicology Mikael Englund has been part of Cellartis’ stem cell team since 2001
Stem cell derivatives in screening
and moved to develop UK operations in Dundee 2007. The UK site
15:00 Panel discussion
Q1: How predictive are stem cell based discovery systems? Is there manufactures large scale volumes of human ESCs and develops advanced
added value above existing systems? culture technology and engineering tools, e.g. for drug screening and
Q2: Are stem cell based platforms compatible with the time lines and
automation systems required in an industrial environment? other applications. The facility also partners with Novo Nordisk to find a
Q3: What is the future for stem cell based discovery systems in the drug cure for diabetes.
discovery pipeline
Mikael’s responsibilities at Cellartis have ranged from fundamental
About the workshop hESC research to industrial production of hESCs for screening. He has a
Demands for better models of human disease and more predictive screening large network in the field and more than nine years experience of the
assays to reduce late stage drug attrition, have promoted a growing interest in
applying pluripotent stem cells (PSCs) and their derivatives at various points in challenges of commercial stem cell business. He has a M.Sc. in molecular
the drug discovery pipeline. Furthermore, the use of PSCs in identifying small biology and a Ph.D. in Medicine.
molecules active in directing cellular reprogramming or differentiation, is a
particularly promising tool for the regenerative medicine field.
This workshop will review recent advances in the field including issues
surrounding cell quality, supply and banking, assay development and the screening
Daniella Steel
process. It will evaluate the benefits of using 3D models, as well as address the
efficacy of PSC-based models for assessing human developmental, cardiac and Daniella Steel is a senior scientist at Cellartis, within R&D at the
hepatic toxicity. Case studies of different compound screening campaigns using
PSCs and their derivatives, will permit exploration of the field in detail. Gothenburg site, Sweden. Daniella is involved in the differentiation
Lessons learned: and application of stem cell-derived cardiomyocytes. Her interests
• Examples of scaled up pluripotent stem cell culture for industrial applications include the innovation and commercialision of stem cell based tools for
• Assay design considerations drug discovery and safety assessment. Through developing industrial
• Examination of screening platforms and strategies applications, Daniella has worked closely with pharmaceutical industry
• A review of stem cell derivatives for screening and biosensor technology providers.
Daniella earned her Ph.D. in electrophysiology from the faculty of Medicine,
Imperial College, London. Her background in establishing cellular disease
About Cellartis: models continued with international experience at McGill University,
Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells
and technology for drug discovery research, toxicity testing and regenerative medicine. Since Canada, and at Chalmers University of Technology, Sweden.
2001, Cellartis has worked globally with industry and academia, platform providers and
end users, to develop the next generation of advanced stem cell products and technologies.
The company leverages deep experience in stem cell handling, scale up and differentiation
into mature and functional human cells. The company was first in the world to bring to the Paul Andrews
market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as
drug discovery tools today. I obtained a Biochemistry B.Sc and Ph.D in Molecular Biology from the
About The Drug Discovery Unit, University of Dundee University of Sheffield. In 1993 I moved to the University of Dundee, to
The Drug Discovery Unit (DDU) based in the College of Life Sciences at the University of pursue my interest in signalling, first using budding yeast and, later, using
Dundee, is a unique example of academic drug discovery. The remit of the DDU is to tackle
high-risk and/or novel targets in areas of unmet medical need. The DDU has all of the human cells. Since 2007 I have been leading the Stem Cell Programme
capabilities required for early phase drug discovery: from assay development, HTS and cell
biology, to medicinal chemistry, structural biology, computational chemistry and ADME/
in the Drug Discovery Unit at Dundee. I established the high-content
DMPK. All of these capabilities operate under one management structure to ensure an screening capabilities and headed several successful screening campaigns
integrated approach and rapid progress.
Currently the team is about 30 people and includes substantial experience from the using human ES cells or their derivatives. My current interests lie in
pharmaceutical/ biotech sector. Since 2007 the DDU has collaborated with Cellartis using hES targeting signalling pathways using small molecules to: engineer cell
cells and their derivatives in high-throughput screening campaigns, to find small molecules
able to manipulate stem cell fate. fate; induce nuclear reprogramming and target cancer stem cells.

4. Day 1
2nd Annual Cell-Based Assays
Wednesday 12th October 2011
09:00 Registration and refreshments
14:40 Label-free methods- where are we and what are
09:30 Opening address from the Chair the prospects for the future?
PANEL DISCUSSION
Rachel Russell D
espite their increasing importance, when will it be commercially viable to
Director, Primary Pharmacology Group integrate non-invasive methods into HT screening? Can relevant quantities
Pfizer of primary cells be secured to enable this? The utility of label-free methods
to reduce attrition rates and the conditions necessary to obtain real-time,
09:40 Impact of new technologies for cellular screening quantitative measurements will be thoroughly assessed. Join this lively
along the drug value chain session and email your questions to: carrie.lancaster@visiongainglobal.com.
• Primary, stem cell, 3D and label-free screens employing cellular assays
Chair: Magalie Rocheville, Investigator, GlaxoSmithKline
• Ion channel screening
• Atomic force microscopy in drug discovery and development Mark Slack, Group Leader, Cellular Assays, Evotec
Mark Slack, Group Leader, Cellular Assays, Evotec Miroslav Cik, Research Fellow, Janssen Pharmaceutica
Clemens Möller, Professor of Biophysics, (Johnson & Johnson)
Albstadt-Sigmaringen University Molly Stevens, Professor of Biomedical Materials and Regenerative
Medicine, Imperial College London
10:20 A novel, rapid and automated method for creating
3D tissue models to study complex cell behaviour
15:20 Development of cell-based methodologies relevant
• What type of information can 3D tissue models provide?
• What is preventing widespread adoption of 3D tissue models? to ion channel drug discovery
• The route to scalable and tuneable 3D tissue models • irect and indirect measurement of ligand- and ion-gated channels in
D
Rosemary Drake recombinant lines
Chief Scientific Officer • Electrophysiology using stem cell derived neurons
TAP Biosystems • Native tissue electrophysiology
Fiona Harris
11:00 Morning refreshments Senior Scientist
Scottish Biomedical
11:20 Unlocking the potential of 3D cell culture with
Alvetex technology 15:40 Afternoon refreshments
• 2D vs 3D cell culture
• Development of unique scaffold 16:00 Development of a multiplexed gene expression
• Optimizing routine 3D cell culture assay in primary neurons
Stefan Przyborski • uantification of compound-induced changes to expression of pain-related genes
Q
Founder and Chief Scientific Officer • hallenges of using native neuronal cells as reagents for primary screening
C
Reinnervate • pplication of the assay for compound profiling and new target identification
A
Darren Cawkill
11:40 Application of a 3D tumour cell culture model to Associate Director, Primary Pharmacology Group
compound screening Pfizer
• Three dimensional growth assay and image analysis
• Plate-based, label-free, high-content analysis evaluation 16:40 The FDSS series: a versatile platform for HTS and
• Screening validation and pre-clinical results assay development
Miroslav Cik • Primary culture and cell line assays in fluorescence and luminescence
Research Fellow • Whole dispensing and imaging screening systems for cell-based assays
Janssen Pharmaceutica (Johnson & Johnson) • Applications: new epilepsy model and luminescence multiplexing
Christelle Catone
12:20 Integration of label-free detection methods in FDSS Application Scientist, Systems Division
GPCR drug discovery Hamamatsu Photonics
• Comparison of impedance and optical read-outs
• Recombinant cells vs endogenous GPCR signalling 17:00 Executable cell biology
• Native receptor activity in disease-relevant cells • Mathematical versus computational models
Magdalena Birker-Robaczewska • Models for executable biology
Senior Lab Head, Cardiovascular & Fibrosis Biology • Challenges for testing dynamics in complex systems
Actelion Pharmaceuticals Jasmin Fisher
Researcher, Executable Biology
13:00 Networking lunch Microsoft Research Cambridge
14:00 Rapid non-invasive analysis of live cells 17:40 Closing remarks from the Chair
• Global fingerprinting of cells with live cell Raman spectroscopy
• Applications in toxicology
• Applications in cell differentiation 17:50 Networking drinks
Molly Stevens Take your discussions further and build new
Professor of Biomedical Materials and Regenerative Medicine relationships in a relaxed and informal setting
Imperial College London
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011

5. Day 2
2nd Annual Cell-Based Assays
Thursday 13th October 2011
09:00 Registration and refreshments 14:00 Enabling technology to enhance cell differentiation
and function in vitro
• ell differentiation in 3D culture using primary MSCs and pluripotent stem cells
C
09:30 Opening address from the Chairs
• evelopment of small molecules to control reproducible human neural
D
Joanne Bowes
differentiation in vitro
Principal Scientist/Team Leader, Safety and Secondary Pharmacology
• se of small molecules to differentiate a 3D skin equivalent model with
U
AstraZeneca
human keratinocytes
Stefan Przyborski
09:40 Early toxicity testing: prediction and Founder and Chief Scientific Officer
tissue-specific models Reinnervate
• Early toxicity testing paradigms
• Cellular models for toxicity testing, focusing on the liver, lung and heart
14:20 Predicting idiopathic cardiotoxicity with 3D heart
• Prediction models using global expression profiling
tissues: combining rodent and human models
Stefan Otto Mueller
• ardiac contractility response to a panel of cardio-toxic drugs with iPSC
C
Director, Early, Genetic and Molecular Toxicology
and ESC based 3D engineered heart tissues
Merck Serono
• Cost-effective and the most predictive screening approach
• dentifying idiopathic cardiotoxicity mechanisms for searching preventive
I
10:20 Protein-fragment complementation assays and strategies
compound profiling Tetsuro Wakatsuki
Anthony Pitt Co-Founder and Chief Scientific Officer
Technical Director Assays and Technology Development InvivoSciences
Lonza
14:50 Generating metabolically active hepatocytes from
10:40 Key considerations in the development of stem pluripotent stem cells
• tem cells offer an unlimited source of hepaotcytes for human drug screening
S
cell assays in predictive toxicology
• Stem cell derived hepatocytes exhibit phenotypic instability in culture
• The need for improved drug screening models to predict risk for man
• e have identified a novel support which stabilises hepatocellular phenotype
W
• rerequisites for successful development of stem cells assays in toxicity testing
P
• C4SM Predictive Toxicology Consortium: challenges and
S David C. Hay
future opportunities Principal Investigator, MRC Centre for Regenerative Medicine
University of Edinburgh
Frank W. Bonner
Chief Executive
Stem Cells for Safer Medicines 15:30 Afternoon refreshments
11:20 Morning refreshments
15:50 Opportunities and challenges for human stem cells
11:40 Therapeutic and research potential of human stem in drug screening
ill hES and hPS/iPS-derived specialised cells better reflect human variation to
W
PANEL DISCUSSION
cells (hSCs) – the GE Healthcare perspective
toxic agents and match biological possibilities with end-user constraints? Can
• How hSCs will revolutionise medical care through regenerative strategies
idiopathic and ethnic libraries aid patient stratification, or will cellular models
• ow hSCs will improve quality, price and accessibility of new pharmaceuticals
H
remain oversimplifications? What new insights will organogenesis and disease
• aximising hSC use in big pharma drug discovery and safety assessment studies
M
models provide? Answers to these and other matters, including regulatory
Stephen Minger requirements and up-scaling for robust industrial production will be addressed.
Global Head of R&D, Cellular Technologies Please email your questions for the panel to: john.shah@visiongainglobal.com.
GE Healthcare
Chair: Julie Holder, Preclinical Director, Stem Cell DPU, GlaxoSmithKline
Stephen Minger, Global Head of R&D, Cellular Technologies, GE Healthcare
12:20 Human pluripotent stem cells (hPSCs) and their use Petter Björquist, Senior Principal Scientist, Project Manager, Cellartis
in drug discovery and cellular assays Frank W. Bonner, Chief Executive, Stem Cells for Safer Medicines
• Importance of scaleable systems for industrial stem cell production David C. Hay, Principal Investigator, MRC Centre for Regenerative
• ellular toxicity testing using hPSC derived cardiomyocytes and hepatocytes
C Medicine, University of Edinburgh
• hPSC technologies compared to traditional in vitro and in vivo assays
Petter Björquist
Senior Principal Scientist, Project Manager
Cellartis
16:30 Chair’s closing remarks
13:00 Networking lunch
16:40 End of conference

6. Registration Form
2nd Annual Cell-Based Assays
11th - 13th October 2011, London, UK
Angel
Conf. code PP Pentonville Road
2nd Annual
Ci
Standard Prices
ty
Cell-Based Assays
Ro
ad
Conference and workshop Fee: £1699 VAT: £339.80 Total: £2038.80
Conference only Fee: £1299 VAT: £259.80 Total: £1558.80 11th - 13th October 2011
Old Street
Workshop only Fee: £599 VAT: £119.80 Total: £718.80 Location: Visiongain Conference Centre Old Street
Number of bookings: Total cost: Address:
230 City Road
City Road
London
Promotional Literature Distribution EC1V 2TT
Distribution of your company’s promotional literature to all conference attendees
UK
Fee: £999 VAT: £199.80 Total: £1198.80
How to book
Details
Email: Piyush.patel@visiongainglobal.com
Forename: Surname: Web: http://www.visiongain.com/cell-based-assays
UK Office:
Job Title: Company: Tel: +44 (0) 20 7549 9961
Fax: +44(0) 20 7549 9932
Main Switchboard Number: Visiongain Ltd
230 City Road
London
Address: EC1V 2QY
UK
General information
Venue: Venue: Directions: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United
Country: Postcode: Kingdom. Closest tube station is Old Street (Northern Line).
Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376
Phone: Fax: 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343
http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html
Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207
Email: 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Signature: Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
I confirm that I have read and agree to the terms and conditions of booking right to charge interest on unpaid invoices.
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
Methods of payment made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
after one month before the start of the event. Should you decide to cancel after this date, the full invoice
Payment must be made in sterling must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
between conferences. However, if you cannot attend the conference, you may make a substitution/name
By Mail: Complete and return your signed registration form together with your cheque payable change at any time, as long as we are informed in writing by email, fax or post. Name changes and
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK substitutions must be from the same company or organisation and are not transferable between
countries. Please note that discounted delegates places at a visiongain event are non refundable.
By Fax: Complete and fax your signed registration form with your credit card details
Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
to +44 (0) 20 7549 9932 excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details
Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
By Bank Transfer: to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
expenses, which may be incurred by the customer as a consequence of the event being postponed or
Visiongain Ltd A/C: visiongain Ltd
cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
Barclays Bank Sort Code: 20-71-64 cost of the registration, travel and expenses.
Piccadilly Branch Account No: 6038 7118 Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
48 Regent Street Swift Code: BARC GB22
Protection Act 1988. Your personal information contained in this form may be used to update you on
visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
London, W1B 5RA IBAN: GB80 BARC 20716460387118 may also share your data with external companies offering complementary products or services. If you
wish for your details to be amended, suppressed or not passed on to any external third party, please
Please debit my credit card: send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
Access MasterCard Visa American Express EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Card number:
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
Expiry Date: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Security number (last 3 digits on back of credit card): Eurocash specialise in recovering cross-border VAT.
How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
Signature: phone. Please ensure that you complete the registration form in full so that we can contact you.
Unable to attend
Cardholder’s name:
Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
with your payment. You will receive speaker talks in PDFs two weeks after the event.
News updates Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/cell-based-assays